Bremelanotide|CAS 189691-06-3|DC Chemicals

Cas No.:	189691-06-3
Chemical Name:	Bremelanotide PT 141
Synonyms:	Bremelanotide PT 141;N-Acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine (2-7)-lactam;PT-141;bremelanotide;BRMELANOTICE;PT 141;Bremelanotide,PT141,PT-141;PT141 Acetate,BreMelanotide Acetate;Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH
SMILES:	CCCC[C@H](NC(C)=O)C(N[C@H]1CC(NCCCC[C@H](NC([C@@H](NC([C@@H](NC([C@H](NC([C@@H](NC1=O)CC2=CN=CN2)=O)CC3=CC=CC=C3)=O)CCCNC(N)=N)=O)CC4=CNC5=CC=CC=C45)=O)C(O)=O)=O)=O
Formula:	C₅₀H₆₈N₁₄O₁₀
M.Wt:	1025.16
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

COA

Cat. No.	Product name	Field of application
DC73463	CRN04894	CRN04894 is a highly potent, selective, orally available melanocortin 2 receptor (MC2R antagonist) antagonist with Ki of 2.1 nM.
DC70135	Bremelanotide	A peptide, non-selective melanocortin receptor agonist for treatment for female sexual dysfunction; selectively stimulates solicitational behaviors in the female rat, without affecting lordosis, pacing, or other sexual behaviors, does not cause generalized motor activation; a peptide analogue of α-MSH.
DC46982	Setmelanotide acetate	Setmelanotide (RM-493, BIM-22493, CAM 4072) is a cyclic peptide full agonist of melanocortin-4 receptor (MC4R) with an EC50 of 0.27 nM and a Ki of 2.1 nM.
DC41671	HS014	HS014 is a potent and selective melanocortin-4 (MC4) receptor antagonist, with Kis of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors, respectively. HS014 modulates the behavioral effects of morphine in mice. HS014 increases food intake in free-feeding rats.
DC11083	Dersimelagon	Dersimelagon, also known as MT-7117 and WHO 10832, is a novel, orally-administered, small molecule, selective melanocortin-1 receptor (MC1R) agonist that increases skin melanin without sun exposure and is being developed to increase light tolerance in EPP/XLP patients. Dersimelagon significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial.